JG
DCPH

Jefferies Group’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Jefferies Group’s Portfolio DCPH Stock Details DCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$3.24M Sell
175,148
-515,852
-75% -$8.1M 0.03% 458
2022
Q2 		$9.09M Sell
691,000
-175,000
-20% -$1.93M 0.08% 213
2022
Q1 		$8.03M Buy
866,000
+853,547
+6,854% +$7.26M 0.05% 281
2021
Q4 		$122K Buy
12,453
+4,155
+50% +$78.1K ﹤0.01% 1451
2021
Q3 		$282K Sell
8,298
-38,660
-82% -$1.23M ﹤0.01% 1378
2021
Q2 		$1.72M Buy
46,958
+29,131
+163% +$1.13M 0.01% 797
2021
Q1 		$799K Buy
+17,827
New +$830K 0.01% 970
2020
Q4 		– Sell
-6,550
Closed -$388K – 1860
2020
Q3 		$336K Sell
6,550
-10,554
-62% -$517K ﹤0.01% 1075
2020
Q2 		$1.02K Buy
17,104
+5,689
+50% +$304K 0.01% 749
2020
Q1 		$470K Sell
11,415
-4,585
-29% -$255K 0.01% 1335
2019
Q4 		$996K Buy
+16,000
New +$760K 0.01% 1464

Other funds holding DCPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Jefferies Group's DCPH Position: Q3 2022 in Review

Jefferies Group reduced its Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) stake by 75% in Q3 2022, selling an estimated $8.1M and leaving 175,148 shares worth $3.24M. The position accounts for 0.03% of the portfolio, ranked #458.

Jefferies Group first reported a position in DCPH in Q4 2019 and has held it in 11 quarters since. The position peaked at $9.09M in Q2 2022. 150 funds tracked by Wall St. Rank hold DCPH as of Q3 2022.

  • Jefferies Group held 175,148 shares of Deciphera Pharmaceuticals, Inc. Common Stock worth $3.24M as of Q3 2022.
  • Jefferies Group sold 515,852 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q3 2022, an estimated $8.1M.
  • Deciphera Pharmaceuticals, Inc. Common Stock made up 0.03% of Jefferies Group's portfolio in Q3 2022, its #458 holding.
  • Jefferies Group first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q4 2019 and has held it in 11 quarters since.
  • Jefferies Group's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $9.09M in Q2 2022.
  • 150 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.